MPH.V
3.5 Million happened in q4. 3.3 million of it is will not reoccur, so I'm exing that out. I feel the company Adjusted earnings estimate of .25 is fair, and I expect earnings to be in the .15-.20 range for the weakest quarter of the year in q1 and we will ramp up from their. I'm very bullish on MPH.V, they also applied their drug for another use if it get approved they will have a monopoly in that area, and guess what unlike KERX they actually do something that I like. Drumroll please. They make money. LOL.
They also have another drug they are developing that is coming along nicely. Plus they own a 5% stake with a right to buy down the line as they have a right to buy Apicore, this company although not part of the financial estimates did 23 million in revs last year and 3.5 ebitda, up from 14 million and 1 ebitda in the year before. Yes right now MPH.V has this one drug, but more uses are possible, another drug is possibly being developed, and they own a stake and a right to buy another massively growing company as well. And the valuation, well there is one they have earnings, and they are growing. All is just my opinion, and I could always be wrong though.
News 
Market Data 
Discover 
AI
